<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4687">
  <stage>Registered</stage>
  <submitdate>9/06/2014</submitdate>
  <approvaldate>9/06/2014</approvaldate>
  <nctid>NCT02173379</nctid>
  <trial_identification>
    <studytitle>Absorb IV Randomized Controlled Trial</studytitle>
    <scientifictitle>A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>10-392 C</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Coronary Artery Disease</healthcondition>
    <healthcondition>Coronary Artery Stenosis</healthcondition>
    <healthcondition>Coronary Disease</healthcondition>
    <healthcondition>Coronary Stenosis</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Absorb BVS
Treatment: devices - XIENCE

Experimental: Absorb BVS - Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS)

Active Comparator: XIENCE - Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition


Treatment: devices: Absorb BVS
Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
Once Absorb GT1 BVS System is commercially available, it can also be used in the ABSORB IV trial. Scaffold diameters: 2.5, 3.0 and 3.5 mm of and scaffold lengths: 8, 12, 18, 23, and 28 mm.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length = 24 mm) with a reference vessel diameter of = 2.5 mm and = 3.75 mm.

Treatment: devices: XIENCE
Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm. The 3.25 mm is only available for XIENCE Xpedition
Stent lengths: 8, 12, 15, 18, 23, and 28 mm
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length = 24 mm) with a reference vessel diameter of = 2.5 mm and = 3.75 mm.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Powered Target lesion failure (TLF) tested for non-inferiority of Absorb BVS to XIENCE. - This analysis will consist of ~2610 subjects in ABSORB IV.</outcome>
      <timepoint>30 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Landmark Target lesion failure (TLF) - TLF is defined as composite of Cardiac Death, Myocardial Infarction (MI) attributable to Target Vessel (TV-MI), or Ischemia-Driven Target Lesion Revascularization (ID-TLR).
This analysis will consist of ~4610 subjects (2000 primary analysis subjects of ABSORB III and 2610 subjects of ABSORB IV).</outcome>
      <timepoint>Between 3 and 7 years (time from 3 year to the first TLF between 3 and 7 years)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Powered TLF, tested for non-inferiority of Absorb BVS to XIENCE - This analysis will consist of ~2610 subjects in ABSORB IV.</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Angina Powered Secondary Endpoint - The percentage of patients who experienced angina within 1 year, tested first for non-inferiority with reflex to superiority against the control.
Angina is defined as any angina or angina equivalent symptoms determined by the physician and/or research coordinator after interview of the patient, and as adjudicated by a clinical events committee (CEC).
This analysis will exclude angina or angina equivalent symptoms that occurred following the index procedure through hospital discharge or 7 days, whichever occurs first.
For subjects who receive a planned staged procedure to treat one or more target lesions, the analysis will exclude angina or angina equivalent symptoms that occurred following the original index procedure through hospital discharge or 7 days after the final procedure, whichever occurs first.
This analysis will consist of ~2610 subjects in ABSORB IV.</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Acute Success- Device success (Lesion level analysis) - Successful delivery and deployment of the study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 30% by quantitative coronary angiography (QCA) (by visual estimation if QCA unavailable). When bailout scaffold/stent is used, the success or failure of the bailout scaffold/stent delivery and deployment is not one of the criteria for device success.</outcome>
      <timepoint>on day 0</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Acute Success- Procedural success (Subject level analysis) - Achievement of final in-scaffold/stent residual stenosis of less than 30% by QCA (by visual estimation if QCA unavailable) with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay (maximum of 7 days).</outcome>
      <timepoint>on day 0</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death (Cardiac, Vascular, Non-cardiovascular) - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</outcome>
      <timepoint>Approximately 7 days (in-hospital)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death (Cardiac, Vascular, Non-cardiovascular) - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death (Cardiac, Vascular, Non-cardiovascular) - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</outcome>
      <timepoint>90 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death (Cardiac, Vascular, Non-cardiovascular) - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death (Cardiac, Vascular, Non-cardiovascular) - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</outcome>
      <timepoint>270 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death (Cardiac, Vascular, Non-cardiovascular) - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death (Cardiac, Vascular, Non-cardiovascular) - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death (Cardiac, Vascular, Non-cardiovascular) - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death (Cardiac, Vascular, Non-cardiovascular) - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death (Cardiac, Vascular, Non-cardiovascular) - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death (Cardiac, Vascular, Non-cardiovascular) - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</outcome>
      <timepoint>6 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death (Cardiac, Vascular, Non-cardiovascular) - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</outcome>
      <timepoint>7 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death (Cardiac, Vascular, Non-cardiovascular) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death (Cardiac, Vascular, Non-cardiovascular) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>9 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death (Cardiac, Vascular, Non-cardiovascular) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Myocardial Infarction (MI) - Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</outcome>
      <timepoint>Approximately 7 days (in-hospital)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Myocardial Infarction (MI) - Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Myocardial Infarction (MI) - Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</outcome>
      <timepoint>90 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Myocardial Infarction (MI) - Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Myocardial Infarction (MI) - Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</outcome>
      <timepoint>270 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Myocardial Infarction (MI) - Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Myocardial Infarction (MI) - Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Myocardial Infarction (MI) - Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Myocardial Infarction (MI) - Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Myocardial Infarction (MI) - Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Myocardial Infarction (MI) - Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</outcome>
      <timepoint>6 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Myocardial Infarction (MI) - Attributable to target vessel (TV-MI)
Not attributable to target vessel (NTV-MI)</outcome>
      <timepoint>7 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Myocardial Infarction (MI) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Myocardial Infarction (MI) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>9 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Myocardial Infarction (MI) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Lesion Revascularization (TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>Approximately 7 days (in-hospital)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Lesion Revascularization (TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Lesion Revascularization (TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>90 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Lesion Revascularization (TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Lesion Revascularization (TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>270 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Lesion Revascularization (TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Lesion Revascularization (TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Lesion Revascularization (TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Lesion Revascularization (TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Lesion Revascularization (TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Lesion Revascularization (TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>6 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Lesion Revascularization (TLR) - TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.</outcome>
      <timepoint>7 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Lesion Revascularization (TLR) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Lesion Revascularization (TLR) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>9 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Lesion Revascularization (TLR) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Vessel Revascularization (TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
-TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.</outcome>
      <timepoint>Approximately 7 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Vessel Revascularization (TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
-TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Vessel Revascularization (TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
-TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.</outcome>
      <timepoint>90 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Vessel Revascularization (TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. classified as: Ischemic driven TVR and Non-ischemic driven TVR.</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Vessel Revascularization (TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
-TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.</outcome>
      <timepoint>270 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Vessel Revascularization (TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
-TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Vessel Revascularization (TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
-TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Vessel Revascularization (TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
-TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Vessel Revascularization (TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
-TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Vessel Revascularization (TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
-TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Vessel Revascularization (TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
-TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.</outcome>
      <timepoint>6 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Vessel Revascularization (TVR) - TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.
-TVR includes both Ischemic driven TVR and Non-ischemic driven TVR.</outcome>
      <timepoint>7 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Vessel Revascularization (TVR) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Vessel Revascularization (TVR) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>9 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Vessel Revascularization (TVR) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All coronary revascularization</outcome>
      <timepoint>Approximately 7 days (in-hospital)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All coronary revascularization</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All coronary revascularization</outcome>
      <timepoint>90 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All coronary revascularization</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All coronary revascularization</outcome>
      <timepoint>270 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All coronary revascularization</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All coronary revascularization</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All coronary revascularization</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All coronary revascularization</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All coronary revascularization</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All coronary revascularization</outcome>
      <timepoint>6 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All coronary revascularization</outcome>
      <timepoint>7 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All coronary revascularization - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All coronary revascularization - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>9 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All coronary revascularization - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI - All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</outcome>
      <timepoint>Approximately 7 days (in-hospital)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI - All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI - All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</outcome>
      <timepoint>90 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI - All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI - All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</outcome>
      <timepoint>270 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI - All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI - All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI - All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI - All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI - All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI - All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</outcome>
      <timepoint>6 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI - All deaths includes
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
-Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.</outcome>
      <timepoint>7 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>9 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</outcome>
      <timepoint>Approximately 7 days (in-hospital)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</outcome>
      <timepoint>90 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</outcome>
      <timepoint>270 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</outcome>
      <timepoint>6 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI - Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</outcome>
      <timepoint>7 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>9 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/TV-MI/ID-TLR (TLF)</outcome>
      <timepoint>Approximately 7 days (in-hospital)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/TV-MI/ID-TLR (TLF)</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/TV-MI/ID-TLR (TLF)</outcome>
      <timepoint>90 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/TV-MI/ID-TLR (TLF)</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/TV-MI/ID-TLR (TLF)</outcome>
      <timepoint>270 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/TV-MI/ID-TLR (TLF)</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/TV-MI/ID-TLR (TLF)</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/TV-MI/ID-TLR (TLF)</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/TV-MI/ID-TLR (TLF)</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/TV-MI/ID-TLR (TLF)</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/TV-MI/ID-TLR (TLF)</outcome>
      <timepoint>6 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/TV-MI/ID-TLR (TLF)</outcome>
      <timepoint>7 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/TV-MI/ID-TLR (TLF) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/TV-MI/ID-TLR (TLF) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>9 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/TV-MI/ID-TLR (TLF) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE)</outcome>
      <timepoint>Approximately 7 days (in-hospital)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR (MACE)</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR (MACE)</outcome>
      <timepoint>90 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR (MACE)</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR (MACE)</outcome>
      <timepoint>270 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR (MACE)</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR (MACE)</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR (MACE)</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR (MACE)</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR (MACE)</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR (MACE)</outcome>
      <timepoint>6 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR (MACE)</outcome>
      <timepoint>7 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR (MACE) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR (MACE) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>9 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR (MACE) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR/ID-TVR, non TL (Target Vessel Failure, TVF)</outcome>
      <timepoint>Approximately 7 days (in-hospital)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR/ID-TVR, non TL (TVF)</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR/ID-TVR, non TL (TVF)</outcome>
      <timepoint>90 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR/ID-TVR, non TL (TVF)</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR/ID-TVR, non TL (TVF)</outcome>
      <timepoint>270 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR/ID-TVR, non TL (TVF)</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR/ID-TVR, non TL (TVF)</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR/ID-TVR, non TL (TVF)</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR/ID-TVR, non TL (TVF)</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR/ID-TVR, non TL (TVF)</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR/ID-TVR, non TL (TVF)</outcome>
      <timepoint>6 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR/ID-TVR, non TL (TVF)</outcome>
      <timepoint>7 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR/ID-TVR, non TL (TVF) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR/ID-TVR, non TL (TVF) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>9 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Death/All MI/ID-TLR/ID-TVR, non TL (TVF) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI/All revascularization (DMR)</outcome>
      <timepoint>Approximately 7 days (in-hospital)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI/All revascularization</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI/All revascularization</outcome>
      <timepoint>90 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI/All revascularization</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI/All revascularization</outcome>
      <timepoint>270 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI/All revascularization</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI/All revascularization</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI/All revascularization</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI/All revascularization</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI/All revascularization</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI/All revascularization</outcome>
      <timepoint>6 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI/All revascularization</outcome>
      <timepoint>7 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI/All revascularization - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI/All revascularization - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>9 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death/All MI/All revascularization - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Scaffold/Stent Thrombosis (per Academic Research Consortium (ARC) definition) - Definite and Probable</outcome>
      <timepoint>Acute (0 - 24 hours post stent implantation)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Scaffold/Stent Thrombosis (per ARC definition) - Definite and Probable</outcome>
      <timepoint>Subacute (&gt;24 hours - 30 days post stent implantation)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Scaffold/Stent Thrombosis (per ARC definition) - Definite and Probable</outcome>
      <timepoint>Late (30 days - 1 year post stent implantation)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Scaffold/Stent Thrombosis (per ARC definition) - Definite and Probable</outcome>
      <timepoint>Very late (&gt;1 year post stent implantation)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rehospitalization - Coronary artery disease (CAD) related
Cardiovascular, non-CAD related
Non-cardiovascular related</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rehospitalization - CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</outcome>
      <timepoint>90 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rehospitalization - CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rehospitalization - CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</outcome>
      <timepoint>270 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rehospitalization - CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rehospitalization - CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rehospitalization - CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rehospitalization - CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rehospitalization - CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rehospitalization - CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</outcome>
      <timepoint>6 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rehospitalization - CAD related
Cardiovascular, non-CAD related
Non-cardiovascular related</outcome>
      <timepoint>7 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rehospitalization - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rehospitalization - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>9 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rehospitalization - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Repeat coronary arteriography</outcome>
      <timepoint>Approximately 7 days (in-hospital)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Repeat coronary arteriography</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Repeat coronary arteriography</outcome>
      <timepoint>90 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Repeat coronary arteriography</outcome>
      <timepoint>180 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Repeat coronary arteriography</outcome>
      <timepoint>270 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Repeat coronary arteriography</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Repeat coronary arteriography</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Repeat coronary arteriography</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Repeat coronary arteriography</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Repeat coronary arteriography</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Repeat coronary arteriography</outcome>
      <timepoint>6 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Repeat coronary arteriography</outcome>
      <timepoint>7 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Repeat coronary arteriography - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Repeat coronary arteriography - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>9 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Repeat coronary arteriography - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on TLF and components</outcome>
      <timepoint>3-4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on TLF and components</outcome>
      <timepoint>3-5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on TLF and components</outcome>
      <timepoint>3-6 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on TLF and components - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>3-8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on TLF and components - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>3-9 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on TLF and components - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>3-10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on MACE and TVF and their components</outcome>
      <timepoint>3-4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on MACE and TVF and their components</outcome>
      <timepoint>3-5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on MACE and TVF and their components</outcome>
      <timepoint>3-6 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on MACE and TVF and their components</outcome>
      <timepoint>3-7 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on MACE and TVF and their components - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>3-8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on MACE and TVF and their components - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>3-9 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on MACE and TVF and their components - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>3-10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on scaffold thrombosis/stent thrombosis (per ARC definition, definite and probable)</outcome>
      <timepoint>3-4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on scaffold thrombosis/stent thrombosis (per ARC definition, definite and probable)</outcome>
      <timepoint>3-5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on scaffold thrombosis/stent thrombosis (per ARC definition, definite and probable)</outcome>
      <timepoint>3-6 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on scaffold thrombosis/stent thrombosis (per ARC definition, definite and probable)</outcome>
      <timepoint>3-7 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on scaffold thrombosis/stent thrombosis (per ARC definition, definite and probable) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>3-8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on scaffold thrombosis/stent thrombosis (per ARC definition, definite and probable) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>3-9 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Landmark analysis on scaffold thrombosis/stent thrombosis (per ARC definition, definite and probable) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>3-10 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Lesion Failure (TLF) - The analysis will be based on 4610 subjects (2000 primary analysis subjects of ABSORB III and 2610 subjects of ABSORB IV)</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Lesion Failure (TLF) - The analysis will be based on 4610 subjects (2000 primary analysis subjects of ABSORB III and 2610 subjects of ABSORB IV)</outcome>
      <timepoint>7 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Lesion Failure (TLF) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>8 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Lesion Failure (TLF) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>9 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Lesion Failure (TLF) - Note: All registered subjects in ABSORB IV will potentially be followed up at 8 years and/or 9 years and/or 10 years via telephone contact/office visit if it is necessary as determined by the Sponsor.</outcome>
      <timepoint>10 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>General 

          1. Subject must be at least 18 years of age.

          2. Subject or a legally authorized representative must provide written Informed Consent
             prior to any study related procedure, per site requirements.

          3. Subject must have evidence of myocardial ischemia (e.g., silent ischemia, stable or
             unstable angina, non-ST-segment elevation MI (NSTEMI), OR recent ST-segment elevation
             MI (STEMI). Patients with stable coronary syndromes can be enrolled any time after
             symptom onset if eligibility criteria are otherwise met. Patients with acute coronary
             syndrome can be enrolled under the following conditions:

               1. Unstable angina or NSTEMI within 2 weeks of the index procedure.

               2. STEMI &gt; 72 hours = 2 weeks prior to the index procedure.

             Note: Subjects with Unstable angina (UA) or NSTEMI or STEMI occurring &gt; 2 weeks of the
             index procedure can be included in the trial but should be categorized based on their
             current angina class.

          4. Subjects must be suitable for PCI. Subjects with stable angina or silent ischemia and
             &lt; 70% diameter stenosis must have objective signs of ischemia as determined by one of
             the following: abnormal stress echocardiogram, nuclear scan, electrocardiogram (ECG),
             positron emission tomography (PET), magnetic resonance imaging (MRI), and/or
             fractional flow reserve (FFR).

             (Note: subject with silent ischemia must have a prior history of typical angina,
             angina-equivalent symptoms, or atypical angina within the past year to be included in
             the trial.)

          5. Subject must be an acceptable candidate for coronary artery bypass graft (CABG)
             surgery.

          6. Female subject of childbearing potential who does not plan pregnancy for up to 1 year
             following the index procedure. For a female subject of childbearing potential a
             pregnancy test must be performed with negative results known within 7 days prior to
             the index procedure per site standard.

          7. Female subject is not breast-feeding at the time of the screening visit and will not
             be breast-feeding for at least 1 year following the index procedure.

          8. Subject agrees to not participate in any other investigational or invasive clinical
             study for a period of 5 years following the index procedure.

        Angiographic 

        Treatment of up to three de novo lesions in a maximum of two epicardial vessels, with a
        maximum of two lesions per epicardial vessel. If only a single lesion is to be treated, it
        must be a target lesion. Up to one non-target lesion can be treated. Non-target lesion
        treatment can occur only in a non-target vessel.

        If there are two target lesions within the same epicardial vessel, the two target lesions
        must be at least 15 mm apart per visual estimation; otherwise this is considered as a
        single target lesion for lesion (and stent) length determination and must be treated with a
        single study device.

        1. Target lesion(s) must be located in a native coronary artery with a visually estimated
        or quantitatively assessed %DS of =50% and &lt; 100%, with a thrombolysis in myocardial
        infarction (TIMI) flow of = 1, and one of the following: stenosis = 70%, an abnormal
        functional test (e.g., fractional flow reserve =0.80 AND/OR a positive stress test), or
        presentation with an acute coronary syndrome (unstable angina or NSTEMI within 2 weeks of
        index procedure, or STEMI &gt;72 hours but = 2 weeks prior to the index procedure).

          1. Target lesion(s) must be located in a native coronary artery with reference vessel
             diameter (RVD) by visual estimation of = 2.50 mm and = 3.75 mm.

          2. Target lesion(s) must be located in a native coronary artery with length by visual
             estimation of = 24 mm.

        Note: Subjects with Unstable angina (UA) or NSTEMI or STEMI occurring &gt; 2 weeks of the
        index procedure can be included in the trial but should be categorized based on their
        current angina class.

        Note: To exclude enrollment of excessively small vessels, if the operator believes that
        based on visual angiographic assessments, the distal reference vessel diameter is = 2.75 mm
        such that the plan is to implant a 2.5 mm device (stent or scaffold) in a target lesion, it
        is strongly recommended that either on-line QCA or intravascular imaging (ultrasound or
        optical coherence tomography) is used and demonstrates that the measured distal RVD for
        this target lesion is = 2.50 mm (by at least one of these imaging modalities). This
        measurement may be performed before or after pre-dilatation, but before randomization. If
        the distal RVD measures &lt;2.5 mm, that lesion IS NOT ELIGIBLE for randomization. Such a
        lesion may be treated as a non-target lesion.

        General</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Any surgery requiring general anesthesia or discontinuation of aspirin and/or a P2Y12
             receptor inhibitor is planned within 12 months after the procedure.

          2. Subject has known hypersensitivity or contraindication to device material and its
             degradants (everolimus, poly (L-lactide), poly (DL-lactide), lactide, lactic acid) and
             cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot
             be adequately pre-medicated. Subject has a known contrast sensitivity that cannot be
             adequately pre-medicated.

          3. Subject has known allergic reaction, hypersensitivity or contraindication to any of
             the following: aspirin; or clopidogrel and prasugrel and ticagrelor; or heparin and
             bivalirudin, and therefore cannot be adequately treated with study medications.

          4. Subject had an acute STEMI (appropriate clinical syndrome with =1 mm of ST-segment
             elevation in =2 contiguous leads) within 72 hours of the index procedure.

          5. Subject has a cardiac arrhythmia identified at the time of screening for which at
             least one of the following criteria is met:

               1. Subject requires coumadin or any other agent for chronic oral anticoagulation.

               2. Subject is likely to become hemodynamically unstable due to their arrhythmia.

               3. Subject has poor survival prognosis due to their arrhythmia.

          6. Subject has a left ventricular ejection fraction (LVEF) &lt; 30% assessed by any
             quantitative method, including but not limited to echocardiography, MRI,
             multiple-gated acquisition (MUGA) scan, contrast left ventriculography, PET scan, etc.
             LVEF may be obtained within 6 months prior to the procedure for subjects with stable
             CAD. For subjects presenting with acute coronary syndrome (ACS), LVEF must be assessed
             within 1 week of the index procedure and after ACS presentation, which may include
             contrast left ventriculography during the index procedure but prior to randomization
             in order to confirm the subject's eligibility.

          7. Subject has undergone prior PCI within the target vessel during the last 12 months.
             Prior PCI within the non-target vessel or any peripheral intervention is acceptable if
             performed anytime &gt;30 days before the index procedure, or between a minimum of 24
             hours and 30 days before the index procedure if successful and uncomplicated.

          8. Subject requires future staged PCI of any lesion other than a target lesion identified
             at the time of index procedure; or subject requires future peripheral vascular
             interventions &lt; 30 days after the index procedure.

          9. Subject has received any solid organ transplants or is on a waiting list for any solid
             organ transplants.

         10. At the time of screening, the subject has a malignancy that is not in remission.

         11. Subject is receiving immunosuppressant therapy or has known immunosuppressive or
             severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., human
             immunodeficiency virus, systemic lupus erythematosus, etc.). Note: corticosteroids are
             not included as immunosuppressant therapy.

         12. Subject has previously received or is scheduled to receive radiotherapy to a coronary
             artery (vascular brachytherapy), or the chest/mediastinum.

         13. Subject is receiving or will require chronic anticoagulation therapy (e.g., coumadin,
             dabigatran, apixaban, rivaroxaban, edoxaban or any other related agent for any
             reason).

         14. Subject has a platelet count &lt; 100,000 cells/mm3 or &gt; 700,000 cells/mm3.

         15. Subject has a documented or suspected hepatic disorder as defined as cirrhosis or
             Child-Pugh = Class B.

         16. Subject has renal insufficiency as defined as an estimated glomerular filtration rate
             (GFR) &lt; 30 ml/min/1.73m2 or dialysis at the time of screening.

         17. Subject is high risk of bleeding for any reason; has a history of bleeding diathesis
             or coagulopathy; has had a significant gastrointestinal or significant urinary bleed
             within the past six months.

         18. Subject has had a cerebrovascular accident or transient ischemic neurological attack
             (TIA) within the past six months, or any prior intracranial bleed, or any permanent
             neurologic defect, or any known intracranial pathology (e.g. aneurysm, arteriovenous
             malformation, etc.).

         19. Subject has extensive peripheral vascular disease that precludes safe 6 French sheath
             insertion. Note: femoral arterial disease does not exclude the patient if radial
             access may be used.

         20. Subject has a life expectancy &lt;5 years for any non-cardiac or cardiac cause.

         21. Subject is in the opinion of the Investigator or designee, unable to comply with the
             requirements of the study protocol or is unsuitable for the study for any reason. This
             includes completion of Patient Reported Outcome instruments.

         22. Subject is currently participating in another clinical trial that has not yet
             completed its primary endpoint.

         23. Subject is part of a vulnerable population who, in the judgment of the investigator,
             is unable to give Informed Consent for reasons of incapacity, immaturity, adverse
             personal circumstances or lack of autonomy. This may include: Individuals with a
             mental disability, persons in nursing homes, children, impoverished persons, persons
             in emergency situations, homeless persons, nomads, refugees, and those incapable of
             giving informed consent. Vulnerable populations also may include members of a group
             with a hierarchical structure such as university students, subordinate hospital and
             laboratory personnel, employees of the Sponsor, members of the armed forces, and
             persons kept in detention.

        Angiographic 

        All exclusion criteria apply to the target lesion(s) or target vessel(s).

          1. Unsuccessful pre-dilatation, defined as the presence of one or more of the following
             (note: successful pre-dilatation of at least one target lesion is required prior to
             randomization):

               1. Residual %diameter stenosis (DS) after pre-dilatation is = 40% (per visual
                  estimation). Note: achieving a %DS = 20% prior to randomization is strongly
                  recommended.

               2. TIMI flow grade &lt;3 (per visual estimation).

               3. Any angiographic complication (e.g. distal embolization, side branch closure).

               4. Any dissection NHLBI grade D-F.

               5. Any chest pain lasting &gt; 5 minutes.

               6. Any ST-segment depression or elevation lasting &gt; 5 minutes.

          2. Lesion is located in left main or there is a =30% diameter stenosis in the left main
             (unless the left main lesion is a protected left main (i.e. a patent bypass graft to
             the LAD and/or LCX arteries is present), and there is no intention to treat the
             protected left main lesion).

          3. Aorto-ostial right coronary artery (RCA) lesion (within 3 mm of the ostium).

          4. Lesion located within 3 mm of the origin of the left anterior descending artery (LAD)
             or left circumflex artery (LCX).

          5. Lesion involving a bifurcation with a:

               1. side branch = 2 mm in diameter, or

               2. side branch with either an ostial or non-ostial lesion with diameter stenosis
                  &gt;50%, or

               3. side branch requiring dilatation

          6. Anatomy proximal to or within the lesion that may impair delivery of the Absorb BVS or
             XIENCE stent:

               1. Extreme angulation (= 90) proximal to or within the target lesion.

               2. Excessive tortuosity (= two 45 angles) proximal to or within the target lesion.

               3. Moderate or heavy calcification proximal to or within the target lesion. If
                  intravascular ultrasound (IVUS) used, subject must be excluded if calcium arc in
                  the vessel prior to the lesion or within the lesion is = 180.

          7. Lesion or vessel involves a myocardial bridge.

          8. Vessel has been previously treated with a stent and the target lesion is within 5 mm
             proximal or distal to a previously stented lesion.

          9. Target lesion located within an arterial or saphenous vein graft or distal to any
             arterial or saphenous vein graft.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>2610</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/04/2024</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC,WA</recruitmentstate>
    <hospital>Liverpool Hospital - Liverpool</hospital>
    <hospital>Prince of Wales Public Hospital - Randwick</hospital>
    <hospital>The Prince Charles Hospital - Brisbane</hospital>
    <hospital>Royal Brisbane Womens - Herston</hospital>
    <hospital>St. Vincent's Hospital Melbourne - Fitzroy</hospital>
    <hospital>Epworth Healthcare Hospital - Richmond</hospital>
    <hospital>Fiona Stanley Hospital - Murdoch</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>2170 - Liverpool</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>4032 - Brisbane</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>3121 - Richmond</postcode>
    <postcode>6150 - Murdoch</postcode>
    <postcode>6001 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Montana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden-Wrttemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bavaria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hesse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Lower Saxony</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>North Rhine-Westphalia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Rhineland-Palatinate</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Schleswig-Holstein</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Abbott Vascular</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>ABSORB IV is a prospective, randomized (1:1, Absorb BVS to XIENCE), single-blind,
      multi-center study, registering approximately 2610 subjects from approximately 140 sites in
      the United States and outside the United States. ABSORB IV is a continuation of ABSORB III
      (NCT01751906) trial which are maintained under one protocol because both trial designs are
      related. The data from ABSORB III and ABSORB IV will be pooled to support the ABSORB IV
      primary endpoint. Both the trials will evaluate the safety and effectiveness of Absorb BVS.

      The ABSORB IV Randomized Controlled Trial (RCT) is designed to continue to evaluate the
      safety and effectiveness as well as the potential short and long-term benefits of Abbott
      Vascular Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1 BVS System
      (once commercially available), as compared to the commercially approved, control stent
      XIENCE.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02173379</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gregg W Stone, MD</name>
      <address>Columbia University Medical Center, New York, NY</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>